Tectonic Therapeutic Inc. (TECX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45's engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b data. With a $253.8M cash balance, TECX is funded for phase 2; positive topline data in 2026 could unlock a $0.6B–$1.8B U.S. peak sales opportunity.
Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC lowered its stake in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 15.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 138,595 shares of the company's stock after selling 25,088 shares during the quarter. Tectonic Therapeutic accounts
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point
Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF) patients. TECX is targeting CpcPH patients with PVR >3 in the ongoing phase 2 APEX study of PH-HFpEF, with topline data expected in 2026 and expansion into PH-ILD planned then also. TECX holds $268.4 million in cash, sufficient to fund operations into Q4 2028 and support multiple clinical milestones, including several catalysts.
Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript
Tectonic Therapeutic, Inc. ( TECX ) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients October 29, 2025 4:30 PM EDT Company Participants Alise Reicin - President, CEO, Secretary & Director Marcella Ruddy - Chief Medical Officer Conference Call Participants Frances Dovell - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Alexander Nackenoff - Truist Securities, Inc., Research Division Martin Auster - Raymond James & Associates, Inc., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Presentation Operator Good day, and welcome to the TX45 Phase Ib Part B PH-HFrEF data conference call. [Operator Instructions] As a reminder, this call may be recorded.
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF
We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026.
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Positive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study using TX45 for the treatment of patients with pulmonary hypertension heart failure with reduced ejection fraction, expected in 2nd half of 2025. In the 7 major markets, the heart failure market is expected to grow to $33.7 billion in 2032.
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing address limitations of native relaxin, positioning it as a potential best-in-class therapeutic. With favorable phase 1a data and ongoing phase 1b and 2 trials, Tectonic's TX45 could become a market leader, potentially attracting interest from potential biopharma acquirers.
Tectonic Therapeutic: Interesting CV Disease Drug Developer
Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027.
TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34.
